This site provides information on the EPIC study and details on case recruitment for veterinary professionals worldwide. Pimobendan is a prescription only medicine, licensed for the treatment of congestive heart failure due to mitral valve disease or dilated cardiomyopathy.

The EPIC Trial site is intended for veterinary professionals. By clicking 'Continue' you are affirming that you are a veterinary professional.

Evaluating Pimobendan in Cardiomegaly
Media & Journalists  •  Contact  •  Helpful Links  •  FAQs  •  Site Map

Managing MMVD & CHF

How are MMVD and CHF diagnosed?

The diagnosis of CHF due to MMVD is usually preceded by the detection of a heart murmur during routine veterinary check-ups using a stethoscope. A heart murmur is the sound caused by blood leaking backward into the atrium from the ventricle. 


To diagnose CHF the veterinarian will need to complete a thorough clinical history and physical examination. They may also recommend some of the following tests:

  • Radiographs (X-rays): to check for any enlargement of the heart or fluid accumulation in the lungs
  • Echocardiography (ultrasound): to show any thickening of the heart valve edges or enlargement of the chambers of the heart
  • Blood tests


Is there a cure for CHF in dogs?

Currently there is no cure for CHF in dogs caused by MMVD but treatments are available to help dogs live a longer life and feel better. The success of any treatment, however, depends on various factors, including early detection and diagnosis.

How are MMVD and CHF managed?

Treatment of CHF due to MMVD begins when the dog shows clear clinical signs of heart failure, and is tailored for the individual dog. Since surgery to prevent further deterioration is rarely possible in canine patients, management of heart failure seeks to improve quality of life and extend life expectancy, usually through daily medication.


Investigator Sign in

Investigators, please sign in here.